Distinguished in Intersex

Andrea M. Isidori

Rome, IT 
Distinguished in Intersex
Rome, IT 
OverviewLocationsClinical Research

Overview

Andrea Isidori practices in Rome, Italy. Ms. Isidori is rated as a Distinguished expert by MediFind in the treatment of Intersex. Her top areas of expertise are Addison's Disease, Hypogonadism, Cushing's syndrome, Hormone Replacement Therapy (HRT), and Parathyroidectomy.

Her clinical research consists of co-authoring 269 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 25 articles and participated in 1 clinical trial in the study of Intersex.

Gender
Female

Locations

Rome, Italy
Other Locations
Sapienza, Italy
Salerno, Italy
Milan, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)
Enrollment Status: Terminated
Publish Date: October 15, 2024
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 2
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly
Enrollment Status: Completed
Publish Date: May 12, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 2
Changes in the Hypothalamic-pituitary Region of Patients With Metabolic Syndrome and Obesity
Changes in the Hypothalamic-pituitary Region of Patients With Metabolic Syndrome and Obesity
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Behavioral, Procedure
Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)
Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Procedure
Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A
Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.
A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.
Enrollment Status: Completed
Publish Date: April 25, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

269 Total Publications

Environmental and lifestyle factors and risk of thyroid carcinoma: a cross-sectional study.
Environmental and lifestyle factors and risk of thyroid carcinoma: a cross-sectional study.
Journal: Endocrine
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Isidori's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 13 Advanced Conditions
View All 67 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile